Section Arrow
Quote
INBX.NASDAQ
- Inhibrx Biosciences Inc.
Quotes are at least 15-min delayed:2026/06/01 04:55 EDT
Pre Market
Last
 --
-- (--)
Bid
91
Ask
108
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 104.01
+0.03 (+0.03%)
Day High 
105.41 
Prev. Close
103.98 
1-M High
150.98 
Volume 
245.15K 
Bid
91
Ask
108
Day Low
101.37 
Open
104.12 
1-M Low
98.62 
Market Cap 
1.53B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 107.58 
20-SMA 117.24 
50-SMA 95.85 
52-W High 155.29 
52-W Low 12.72 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.39/-2.14
Enterprise Value
1.63B
Balance Sheet
Book Value Per Share
-1.43
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.30M
Operating Revenue Per Share
0.04
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.1172-0.0468-28.54%-- 
Pre Market 0.0815 -0.0357 -30.46%
REPLReplimune Group8.69+4.01+85.68%-- 
Pre Market 9.78 +1.09 +12.54%
CDTCDT Equity Inc.1.04+0.0899+9.46%-- 
Pre Market 0.9612 -0.0788 -7.58%
CMNDClearmind Medicine Inc.3.58+1.13+46.12%-- 
Pre Market 2.67 -0.91 -25.42%
OTLKOutlook Therapeutics0.73-0.01-1.35%-- 
Pre Market 0.7002 -0.0298 -4.08%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.